Detect early Parkinson via blood
- Trial ID
- NCT05385315
- Official Title
- Evaluation De La Performance Clinique D'un Nouveau Biomarqueur Sanguin Des Phases Précoces De La Maladie De Parkinson
- Goal
- Detect early Parkinson via blood
- Status
- RECRUITING
- Sponsor
- University Hospital, Grenoble
- Study Type
- OBSERVATIONAL
- Enrollment
- 70 participants
- Conditions
- Parkinson Disease
Plain-Language Summary
The goal is to test a new blood biomarker that could detect Parkinson's disease early and help distinguish Parkinson's from similar conditions like multiple system atrophy. The approach is observational blood sampling to measure a specific molecular signature or disease‑related proteins in the blood, seeing if that signature reliably marks Parkinson's pathology without changing any treatments. Adults 18 and older are eligible if they are newly diagnosed and not yet on dopaminergic drugs, have advanced Parkinson's treated for more than five years, or have multiple system atrophy, while people with deep brain stimulation or other neurodegenerative diseases are excluded.
Locations
- CHU Grenoble Alpes, Grenoble, France
Frequently Asked Questions
- What is this trial testing?
- This trial is studying an experimental treatment. The goal is to test a new blood biomarker that could detect Parkinson's disease early and help distinguish Parkinson's from similar conditions like multiple system atrophy. The approach is observational blood sampling to measure a specific molecular signature or disease‑related proteins in the blood, seeing if that signature reliably marks Parkinson's pathology without changing any treatments. Adults 18 and older are eligible if they are newly diagnosed and not yet on dopaminergic drugs, have advanced Parkinson's treated for more than five years, or have multiple system atrophy, while people with deep brain stimulation or other neurodegenerative diseases are excluded.
- Who can participate?
- Participants must be at least 18 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 3 years.